In an interview with PharmaShots, Laurent Levy, Co-Founder & CEO at Nanobiotix shares his views on the first patient enrollment of NBTXR3 in P-III (NANORAY-312) study for the treatment of head and neck squamous cell carcinoma
Shots:
The first patient has been enrolled in P-III (NANORAY-312) study to evaluate the efficacy & safety of NBTXR3 with/out cetuximab vs radiotherapy with/out cetuximab…
